• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.

    1/23/24 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email

    ALLĒ SOLIDIFIES ITS POSITIONING WITH SATISFACTION SCORES IN THE NINETY-SECOND PERCENTILE BASED ON CONSUMER SURVEY

    IRVINE, Calif., Jan. 23, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the results of a consumer survey designed to examine the value proposition of Allē, Allergan Aesthetics loyalty rewards program. The survey of Allē Members who have been treated in the past twelve months affirmed Allē's position as the leading aesthetics loyalty rewards program in the country, with a ninety-two percent satisfaction rate reported by survey respondents1*.

    In serving more than six million Members across 19,000 practices to-date, part of Allē's mission is to help educate consumers about aesthetic treatments such as BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® Collection of Fillers, SKINVIVE by JUVÉDERM®, CoolSculpting®, SkinMedica®, DiamondGlow®, and more. From its inception, Allē has disrupted the aesthetics industry by offering the most robust rewards program in the category. By providing its Members with information, tools, and incentives, Allē empowers consumers along their treatment journey, making their next product purchase or treatment closer within reach.

    Key Allē features and attributes that keep Allē Members satisfied and engaged include:

    • Cost Savings: The survey found that the primary motivation for becoming an Allē Member was wanting to use an offer to save money on a treatment1.
    • Earn Points, Even on Non-Allē Treatments: Allergan Aesthetics recognizes that people deserve to be rewarded, no matter their treatment regimens. That's why Allē is the first and only aesthetics loyalty rewards program to give its users points on more than 40 brands, products, and treatments at their Allē provider—even those that are not Allē brands.
    • Treatment Education: With original content and information across the app, Allē serves as a partner for discovery to help Members learn about other treatments. In fact, 77% of respondents reported that they found Allē extremely or very valuable in helping them decide what aesthetics brands to ask their provider about ahead of treatment1. That, coupled with more than one million patients reading an Allē article prior to their first treatment, has made the program an invaluable resource to help guide them on their treatment journeys.
    • Exclusive Rewards: Allē Members who accrue 1,200 points within a calendar year can unlock an exclusive, VIP membership called "The A List" that gives them added membership benefits like: points that never expire as long as you're on The A List, the A Line VIP Member support, surprise gifts, and early access to offers and events.

    "With so many aesthetics loyalty rewards programs available, our commitment to continuing to drive value is what keeps us as the preferred platform among consumers and providers," said Jasson W. Gilmore, Senior Vice President, Allergan Data Labs at Allergan Aesthetics. "The value Allē delivers to our customers is twofold: first, we provide consumers with a curated aesthetic experience that is tailored to their individual needs and aesthetic goals. Second, we streamline the provider experience, from creating a seamless in-office experience (like booking an appointment or checking out) and providing insights about consumer treatment behaviors and trends, to helping them retain and attract patients into their practice."

    "Allē for Business, the provider component of Allē, has truly become one of our most trusted in-office tools to acquire and retain aesthetics patients in our practice," said Kathleen Morno M.D., Board Certified Ophthalmologist and Facial Aesthetics Specialist at RL Center for Cosmetic Surgery & Medspa. "From the promotional elements that encourage patients to book an appointment to the patient trends and data that Allē provides to help me offer patients more customized treatment plans, we have seamlessly, and easily, integrated Allē into every touchpoint of our patient experience. With Allē, I can better provide my patients a curated experience that is tailored to their aesthetic goals and helps keep them coming back."

    For consumers interested in participating, please visit www.alle.com to join and start taking advantage of exclusive offers and access. For providers looking to engage with Allē for Business, please contact your local Allergan Aesthetics Business Development Manager.

    *In an online survey, 92% (n = 737) of patients reported they were "Very Satisfied" or "Satisfied" (top 2 out of 5 responses) with their Allē experience.

    About Allergan Aesthetics

    At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

    BOTOX® Cosmetic (onabotulinumtoxinA) Important Safety Information

    BOTOX® Cosmetic (onabotulinumtoxinA) is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet, and frown lines between the eyebrows in adults.

    Talk to your doctor about BOTOX® Cosmetic and whether it's right for you. There are risks with this product—the effects of BOTOX® Cosmetic may spread hours to weeks after injection causing serious symptoms. Alert your doctor right away as difficulty swallowing, speaking, breathing, eye problems or muscle weakness can be a sign of a life-threatening condition. If this happens, do not drive a car, operate machinery, or do other dangerous activities. Patients with these conditions before injection are at the highest risk. Swallowing problems may last for several months. Side effects may include allergic reactions, neck and injection-site pain, fatigue and headache. Allergic reactions can include rash, welts, asthma symptoms, and dizziness. Don't receive BOTOX® Cosmetic if there's a skin infection. Tell your doctor your medical history, muscle or nerve conditions (including ALS/Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome), and medications, including botulinum toxins, as these may increase the risk of serious side effects.

    JUVÉDERM® Collection of Fillers Important Safety Information

    Correct age-related volume loss in the cheek area and add volume to the chin region to improve the chin profile with JUVÉDERM® VOLUMA® XC, improve moderate to severe loss of jawline definition with JUVÉDERM® VOLUX® XC, add volume to improve the appearance of undereye hollows with JUVÉDERM® VOLBELLA® XC, add fullness to lips with JUVÉDERM® ULTRA XC and JUVÉDERM® VOLBELLA ® XC, and smooth moderate to severe lines around the nose and mouth with JUVÉDERM® VOLLURE® XC and JUVÉDERM® ULTRA PLUS XC. The JUVÉDERM® Collection of Fillers are for adults over 21.

    JUVÉDERM® is not for people who have a history of severe allergic reactions or allergies to any of its ingredients, including lidocaine. The effectiveness of removal of any dermal filler has not been studied.

    Tell your doctor if you have a history of scarring or taking medicines that decrease the body's immune response or that can prolong bleeding. Certain medicines and procedures may increase risk of infection, inflammation, bleeding, or bruising at the injection site. Common side effects include injection-site redness, swelling, pain, tenderness, firmness, lumps, bumps, bruising, discoloration, or itching.

    As with all fillers, there's a rare risk of unintentional injection into a blood vessel, which can cause vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring. JUVÉDERM® VOLBELLA® XC for the undereye hollows requires necessary training which can be verified at www.juvederm.com. There is a risk of infection with all skin injection procedures.

    Talk to your licensed specialist and for additional information, including Important Safety Information, visit www.juvederm.com.

    SKINVIVE by JUVÉDERM® Important Safety Information

    SKINVIVE by JUVÉDERM® injectable gel is for improving skin smoothness in the cheeks for adults over 21.

    SKINVIVE by JUVÉDERM® is not for people who have a history of severe allergic reactions or allergies to any of its ingredients, including lidocaine. Tell your specialist if you have a history of scarring or taking medicines that decrease the body's immune response or that can prolong bleeding. Certain medicines and procedures may increase the risk of infection, inflammation, bleeding, or bruising at the injection site. Common side effects were lumps/bumps, swelling, redness, pain, itching, bruising, and discoloration. Additionally, there have been reports outside of the US of inflammation, nodules, unsatisfactory result or loss of/no improvement, allergic reaction, anxiety, blood vessel blockage, infection, dry skin, increase/decrease in sensation, and abscess. There is a rare risk of unintentional injection into a blood vessel with all dermal fillers which can cause vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring. Delayed-onset inflammation and infection at the injection site are events associated with dermal filler injection.

    Talk to your licensed specialist and for additional information, including Important Safety Information, visit www.skinvive.com.

    CoolSculpting® and CoolSculpting® Elite Important Safety Information

    CoolSculpting® and CoolSculpting® Elite are FDA-cleared to treat visible fat bulges on the abdomen, flank, thigh, bra fat, back fat, upper arm, and under the buttocks, chin, and jawline. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments. CoolSculpting® and CoolSculpting® Elite are not a treatment for weight loss. Some common side effects include temporary numbness, discomfort, and swelling. Rare side effects may occur. CoolSculpting® and CoolSculpting® Elite may cause visible enlargement in the treated area after treatment, which will not resolve on its own and may require surgical intervention for correction. Ask your doctor if CoolSculpting® or CoolSculpting® Elite is right for you. See additional Important Safety Information at www.coolsculpting.com. 

    DiamondGlow® Important Safety Information

    The DiamondGlow® device is a general dermabrasion device that gently removes the top layer of skin and delivers topical cosmetic SkinMedica® Pro-Infusion Serums onto the skin. This treatment is not for everyone. Some typical side effects include a scratchy sensation, tightness, and redness. Rare side effects may occur. Please talk to your provider for additional information.

    SkinMedica®

    Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA.

    Reference:

         1.       Data on File. Allergan Data Labs. Allē Member Loyalty Survey, October 2023.

     

    Cision View original content:https://www.prnewswire.com/news-releases/all-by-allergan-aesthetics-is-the-leading-aesthetics-loyalty-rewards-program-in-the-us-302041270.html

    SOURCE AbbVie

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    2/20/2026$275.00Overweight
    Barclays
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    1/7/2026$240.00Neutral
    UBS
    12/10/2025$265.00Hold → Buy
    HSBC Securities
    11/13/2025$280.00Sector Outperform
    Scotiabank
    11/4/2025$237.00Buy → Hold
    DZ Bank
    10/14/2025Buy → Hold
    Erste Group
    More analyst ratings

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on AbbVie with a new price target

    RBC Capital Mkts initiated coverage of AbbVie with a rating of Outperform and set a new price target of $260.00

    2/25/26 7:48:26 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on AbbVie with a new price target

    Barclays initiated coverage of AbbVie with a rating of Overweight and set a new price target of $275.00

    2/20/26 8:23:14 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie downgraded by Wolfe Research

    Wolfe Research downgraded AbbVie from Outperform to Peer Perform

    1/8/26 8:35:39 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS

    Data shows a rise in specific treatment demand; a shift in patient consultation and the rising role of facial volume restoration 67% of patients say MWL treatment changed their goals toward improving appearance, not just weight reductioni.Nearly half of MWL patients (47%) were reported by HCPs to benefit most from hyaluronic acid injectable fillers when addressing post-weight-loss facial concernsii.60% of consumers receiving GLP-1 medications obtain them from providers who also offer aesthetic treatments, up from 49% in late 2024iii.IRVINE, Calif., March 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, shares new data illustrating how the rapid adoption of Medical Weight Loss

    3/4/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Present at the Leerink Partners Global Healthcare Conference

    NORTH CHICAGO, Ill., March 3, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will participate in a fireside chat at 10:20 a.m. Central Time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therape

    3/3/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

    In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for induction delivered by subcutaneous (SC) injection versus placebo1These data support strong efficacy of risankizumab in Crohn's disease while providing potential for an induction choice for patients1The safety profile of risankizumab SC induction was consistent with its known profile in Crohn's disease, with no new safety risks observed1NORTH CHICAGO, Ill., March 2, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled,

    3/2/26 8:30:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    SEC Filings

    View All

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    3/4/26 4:59:47 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    2/26/26 5:14:40 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by AbbVie Inc.

    424B5 - AbbVie Inc. (0001551152) (Filer)

    2/26/26 5:07:32 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, R&D and CSO Thakkar Roopal covered exercise/tax liability with 8,037 shares, decreasing direct ownership by 13% to 52,376 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    3/3/26 6:14:39 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN OF THE BOARD AND CEO Michael Robert A. covered exercise/tax liability with 36,523 shares, decreasing direct ownership by 17% to 178,737 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    3/3/26 6:12:11 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CHIEF FINANCIAL OFFICER Reents Scott T covered exercise/tax liability with 21,638 shares, decreasing direct ownership by 36% to 38,777 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    3/3/26 6:10:11 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

    Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis  Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer

    2/4/26 7:48:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call

    NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key t

    1/7/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care